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Dietary antioxidant inhibits lipoprotein oxidation and renal injury in
experimental focal segmental glomeruloscierosis. Lipid peroxidation may
be involved in the pathogenesis of focal segmental glomerulosclerosis
(FSGS). In the present study we examined whether lipid-soluble antioxi-
dants, probucol and vitamin E, could inhibit renal injury in rats with
chronic puromycin aminonucleoside (PA) nephrosis and dietary hyper-
cholesterolemia by protecting lipoproteins from oxidation. Male Sprague-
Dawley rats received six intraperitoneal injections of PA over a 10 week
period and were fed a high cholesterol (HC) diet (PA-HC) or the same
diet supplemented with either 1% probucol or vitamin E (100 lU/kg) for
32 weeks. For comparison, a group of rats received PA injections and a
normal diet (PA-normal) with or without probucol or vitamin E. Another
group rats received saline injections instead of PA and were fed a HC diet
(Sal-HC) with or without probucol or vitamin E. At the end of the
experiment, proteinuria, FSGS and tubulointerstitial lesions were present
in the untreated rats with PA-HC or PA-normal. The magnitude of these
lesions was significantly greater in the PA-HC rats than the PA-normal. In
contrast to the PA-HC group with hypercholesterolemia, the PA-normal
group did not show hypercholesterolemia from week 16 onwards. The rats
with PA-HC alone showed significantly higher renal cortical malondial-
dehyde (MDA) levels and greater susceptibility of plasma very low density
lipoprotein (VLDL) + low density lipoprotein (LDL) to the copper-
mediated oxidation than the rats with PA-normal or Sal-HC alone. The
administration of probucol or vitamin E in the rats with PA-HC signifi-
cantly reduced the susceptibility of plasma VLDL + LDL to in vitro
oxidation, renal cortical MDA level, proteinuria, mesangial volume den-
sity and magnitude of FSGS and interstitial lesions. Immunohistochemical
staining of renal tissue showed focal segmental distribution of oxidized
LDL (Ox-LDL) in the glomeruli of rats with PA-HC. Administration of
probucol or vitamin E reduced the intensity of Ox-LDL staining. The
staining with ED1 demonstrated that infiltrating glomerular macrophages
were significantly more prevalent in the untreated rats with PA-HC than
PA-normal or Sal-HC. Treatment with probucol or vitamin E significantly
reduced the number of glomerular macrophages in the rats with PA-HC.
These results suggest that alimentary hypercholesterolemia aggravates the
renal damage in association with increased renal lipid peroxides in chronic
PA nephrosis, and that dietary probucol or vitamin E attenuates renal
injury in rats with PA-HC possibly by making lipoproteins resistant to
oxidation and by inhibiting intraglomerutar macrophage infiltration.
Focal segmental glomeruloscierosis (FSGS) in humans is char-
acterized by steroid-resistant nephrotic syndrome and progressive
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deterioration of renal function. The pathogenesis of this disease is
not clearly defined.
As is the case for atherosclerosis, lipid deposits and foam cells
are frequently present in the lesions of FSGS, suggesting that a
common pathogenetic mechanism such as lipoprotein abnormal-
ities may be involved in the formation of these lesions. Studies
have suggested that hypercholesterolemia in nephrosis may play a
role in the progression of initial glomerular injury to FSGS [1—3].
Hypercholesterolemia is mainly due to the increased level of
low-density lipoprotein (LDL). Elevated levels of LDL are a
major risk factor in atherosclerosis, but oxidative modification of
LDL seems to enhance the atherogenesis of LDL [4—8]. Dietary
antioxidant, probucol in particular, protects LDL as well as very
low density lipoprotein (VLDL) against in vitro oxidation [9, 10]
and limits experimental atherosclerosis [11—13].
Puromycin aminonucleoside (PA) is a glomerular visceral epi-
thelial cell toxin. A single intravenous injection of PA in rats
results in acute PA nephrosis, a model of human minimal lesion
[14]. Lesions of FSGS have been observed in rats with chronic PA
nephrosis induced by repeated intraperitoneal injections [151 or a
single central administration of PA [16]. The PA-induced oxidant-
mediated podocyte injury [17] seems to be involved in the
pathogenesis of both acute and chronic PA nephrosis. Indeed,
antioxidants including taurine, vitamin E, probucol and/or sele-
nium attenuated renal injury in rats with acute or chronic PA
nephrosis [18—23].
Normal rats have very low plasma levels of LDL [24]. Although
hypercholesterolemia is almost constantly present in human ne-
phrosis, that in rats with PA-induced nephrotic syndrome [22, 25]
appears to be a transient phenomenon [26]. A high cholesterol(HC) diet in rats with chronic PA nephrosis induces not only
hypercholesterolemia but also aggravation of the FSGS develop-
ment [26, 27]. The mechanisms by which hypercholesterolemia
accelerates the underlying renal disease are not clear; several
factors such as increased intraglomerular macrophage infiltration
[26, 27], increased glomerular capillary pressure [28] and oxidative
modification of LDL [291 seem to be involved. In support of the
hypothesis that oxidized LDL (Ox-LDL) plays a role in the
progression of renal disease is the fact that Ox-LDL has been
shown to occur in the lesions of FSGS in rats with chronic PA
nephrosis and dietary hypercholesterolemia (PA-HC) [30].
Despite the possible relationship between lipid peroxidation
and progressive glomerulosclerosis, no study has explored the
long-term effects of lipid-soluble antioxidants in the rats with
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PA-HC. We hypothesize that alimentary hypercholesterolemia
could make lipoproteins more susceptible to oxidation, and that
the antioxidants could prevent not only PA-induced oxidant-
mediated podocyte injury but also lipoprotein oxidation in the rats
with PA-HC. In the present study, we found that chronic PA
nephrotic rats with dietary hypercholestolemia showed greater
renal lipid peroxides and more severe renal damage than those
without, and that inhibition of in vivo lipid peroxidation by
administration of probucol or vitamin E could slow the progres-
sion of renal damage.
Methods
Experimental protocol
Ten groups of male Sprague-Dawley rats weighing 150 to 200 g
were used. Six of the ten groups received repeated intraperitoneal
injections of PA (initially 60 mg per kg body wt followed by 20 mg
per kg 5 times at 2 week intervals) and were fed either a HC diet
or a standard diet. PA was dissolved in 0.9% NaCl, 10 mg/ml. The
remaining group rats received saline injections instead of PA and
were fed either a HC diet or a standard diet. The standard diet
comprised of 23% protein, 47% carbohydrate and 6% fat. The
HC diet comprised of a standard diet supplemented with 4%
cholesterol and 1% cholic acid (Sigma Chemical Co., St. Louis,
MO, USA). The PA-treated HC-fed (PA-HC) animals received
either no antioxidant (N = 14), or a probucol-added diet contain-
ing probucol 1% by weight (N = 15), or a vitamin E-enriched diet
containing 100 IU vitamin E per kg (N = 15). The PA-treated
normal diet-fed (PA-normal) rats received no antioxidant (N =
5), or a probucol-added diet (N = 5), or a diet with vitamin E(N = 4). The saline-injected HC-fed (Sal-HC) rats received either
no antioxidant (N = 6), or a probucol-enriched diet (N = 6), or a
diet containing vitamin E (N = 4). The tenth group rats received
saline injections and were fed a standard diet (Sal-normal, N = 6).
Probucol and vitamin E were kindly donated by Marion Merrell
Dow Inc. (Cincinnati, OH, USA) and the Shinpoong Pharmaceu-
tical Co. (Seoul, Korea), respectively. The feeding of each diet
started one day after first PA delivery and continued for the entire
experimental period.
The experiment continued for 32 weeks. Urine was collected
during a 24-hour period from rats in metabolic cages at intervals
of four weeks as well as at sacrifice, During collection rats were
allowed free access to water, but food was withdrawn. Urine
protein was quantitated using bicinchoninic acid [311 with bovine
serum albumin as a standard. Tail vein serum samples were also
obtained at intervals of four or eight weeks for determination of
fasting total cholesterol, triglycerides and urea nitrogen.
At the end of the observation period, samples of kidney coronal
sections for immunohistochemistry, light and electron microscopy
and thiobarbituric acid-reactive substances (TBARS) assay were
harvested.
Blood collection and lipoprotein isolation
At 32 weeks, after a 24-hour fast, the rats were exsanguinated (5
to 10 ml blood/rat) with aortic puncture under ether anesthesia
and the plasma was obtained. Plasma cholesterol, triglycerides,
urea nitrogen and creatinine were measured with commercial kits
on a Hitachi 747 automated analyzer. High density lipoprotein
cholesterol (HDL-C) was assayed after dextran sulfate-MgCl2
precipitation of lipoproteins containing apolipoprotein B. Plasma
LDL- plus VLDL-cholesterol (LDL-C + VLDL-C) was derived
from the above data using the modified Friedewald formula [321,
VLDL-C + LDL-C = total cholesterol —(HDL-C + 0.16 X
triglycerides).
The plasma of rats from the same treatment group was pooled
to obtain sufficient quantities for lipoprotein isolation. Since rats
have relatively small amounts of LDL [241, we chose to collect
lipoprotein fractions containing both VLDL and LDL. To isolate
lipoprotein fractions, the solvent density of the plasma was
adjusted to 1.050 g/ml as described previously [33]. After centrif-
ugation for 16 hours at 50,000 rpm, 4°C, the supernatant was
collected as a fraction containing VLDL and LDL. The lipopro-
tein fractions were dialyzed for 24 hours at 4°C against phosphate-
buffered saline (PBS) containing 0.01% EDTA.
Measure of lipid peroxidation
The degree of lipid peroxidation in the renal cortex was
determined by measuring TBARS as described previously [34—
36]. Portions of renal cortical tissue were dissected and homoge-
nized in 100 m sodium carbonate buffer containing 1 ms EDTA
by use of a Potter-Elvehjem smooth glass homogenizer. The
homogenates were centrifuged and supernatants were collected.
After the addition of 1/12 N H2S04 and 10% phosphotungstic acid
to the supernanatants, the mixture was centrifuged. To the
precipitate, 1% thiobarbituric acid, glacial acetic acid and 10 mrvi
FeCI3 were added, and the mixture was boiled. Then n-butanol
and (NH4)2S04 solution were added, and the mixtures were
centrifuged. TBARS in the upper butanol layer were estimated on
a Kontron fluorescence spectrophotometer with excitation at 515
nm and emission at 553 nm. Freshly diluted tetramethoxypropane
(Sigma Chemical Co.), which yields malondialdehyde (MDA),
was used as a standard. The protein content of the homogenates
was measured, and the data were expressed as nmol MDA
equivalents/mg of protein.
The susceptibility of plasma VLDL and LDL fractions of each
animal group to Cu-catalyzed oxidation was also assessed.
Residual EDTA in plasma lipoproteins was removed by dialysis
against PBS without EDTA just before modification trials. The
lipoprotein fractions (250 g/ml) were incubated with freshly
diluted 10 jIM copper in a volume of 2 ml PBS for 24 hours at
37°C. The process was arrested by the addition of 200 jIM EDTA
and 40 jIM butylated hydroxytoluene (BHT). TBARS were deter-
mined as described above.
Tissue processing, histology and immunohistochemistiy
Midline, coronal sections fixed in Zenker's solution were em-
bedded in paraffin, and stained with periodic acid-Schiff (PAS). At
least 200 glomeruli were examined for each animal. FSGS was
defined as segmental loss of vascularity or collapse and solidifi-
cation. The percentage of glomeruli showing segmental sclerosis
was calculated.
Immunohistochemical studies
An avidin-biotin-peroxidase procedure (Dakopatts, Glostrup,
Denmark) for antibody localization was used. To demonstrate in
vivo lipid peroxidation, kidney tissues were snap frozen in isopen-
tane precooled in liquid nitrogen, sectioned and fixed in 4%
paraformaldehyde, 20 jIM BHT, 2 mrvi EDTA, and 5% sucrose.
Endogenous biotin was blocked with avidin D and biotin-blocking
solutions. Two monoclonal antibodies (mAbs), OL-lO and OL-13,
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Table 1. Renal function and plasma lipids in experimental animals after 32 weeks
Group (N)
F dinc
g/day
Body Kidney
weight weight
g
Plasma urea
nitrogen
Plasma
creatinine
Total
cholesterol
LDL + VLDL
cholesterol
HDL
cholesterol Triglycerides
mgldl______
PA-HC
Nontreated (14) 27 8 356 58 1.7 0.2 17.2 2.9 0.65 0.11 282 92 244 116 8.4 5.2 49 14
Probucol-treated (15) 26 8 333 37 1.6 0.3 15.6 2.1 0.58 0.07 225 65 213 64 4.6 4.3 45 14
Vitamin E-treated (15) 25 9 337 37 1.5 0.2 15.5 2.5 0.61 0.06 241 62 228 64 6.3 4.8 50 18
PA-normal
Nontreated (5) 25 8 464 93" 1.8 0.2 16.4 3.1 0.55 0.05 73 22" 44 24" 17.2 1.1" 68 26
Probucol-treated (5) 25 6 398 16 1.8 0.1 14.8 1.6 0.57 0.05 36 10 17 9 13.2 7.1 37 6
Vitamin E-treated (4) 26 9 422 23 1.7 0.1 14.8 1.4 0.57 0.05 52 21 24 23 18.8 9.0 58 26
Sal-HC
Nontreated (6) 25 7 313 15 1.4 0.1 17.4 1.9 0.67 0.02 222 105 203 102 12.7 6.1 39 9
Probucol-treated (6) 26 8 333 33 1.3 0.1 16.2 2.2 0.67 0.04 256 135 272 141 3.0 2.6 51 15
Vitamin E-treated (4) 26 7 396 65 1.7 0.2 17.8 0.1 0.67 0.02 232 99 215 125 8.6 3.1 55 4
Sal-normal (6) 25 7 454 43" 1.7 0.2 14.8 1.6 0.57 0.05 57 15" 20 5" 32.1 9.1" 42 6
Values are mean SD. Abbreviations are: PA-HC, rats with chronic PA nephrosis and high cholesterol (HC) diet; PA-normal, rats with chronic PA
nephrosis and normal diet; Sal-HC, saline-injected rats with HC diet; Sal-normal, saline-injected rats fed a normal diet.
P < 0.05 comparing PA-normal nontreated, Sal-HC nontreated, or Sal-normal versus PA-HC nontreated
specific for Ox-LDL [36J were utilized as primary antibodies.
Biotinylated goat anti-mouse antibody was used as a secondary
antibody. An avidin-biotinylated horseradish peroxidase complex
incubation was carried out, followed by the addition of diamino-
benzidine and diluted H202 solution in sequence. Sections were
counterstained with hematoxylin. Nonspecific antibody reactions
were assessed by omitting the primary mAb.
For demonstration of ED1-positive cells, paraffin-embedded
kidney sections were serially deparaffinized with xylene. Endoge-
nous peroxidase activity was quenched with methanol-H202 solu-
tion. As a primary antibody, ED1 (Accurate Chemical and
Scientific Corp., Westbury, NY, USA), a mouse monoclonal
antibody specific for rat monocytes and macrophages [37], was
utilized. Other procedures were the same as described above for
detection of Ox-LDL. More than fifty glomeruli were scored for
the number of ED1-positive cells observed within the glomeruli.
Morphometiy
Mean glomerular area was determined on the light microscopic
sections at an approximate magnification of x200 as previously
described by point counting [38, 39]. At least 50 glomeruli were
counted for each animal,
Tissue for electron microscopy was fixed in 2.5% glutaralde-
hyde, postfixed in 1% osmium tetroxide, and embedded in epon.
From each group, three to six subjects were randomly selected for
electron microscopic study. Two or three glomeruli were studied
for each subject. Ultrathin sections were stained with uranyl
acetate and lead citrate and photographed at a magnification of
1<2,000 using a Hitach H-60() electron microscope. Glomerular
sections were analyzed using whole reconstruction of the glomer-
ular tuft area with five to eight photomicrographs/glomerulus.
Negatives were enlarged to a uniform print size at a final
magnification of 1<4,600.
To quantitate the volume density of mesangial cells [Vv(mes
cell/glom)] and mesangial matrix [Vv(mes matrix/glom)], a point
counting technique was used as we have previously described [391.
Area density of mesangial cells and mesangial matrix was mea-
sured by placing a grid of points superimposed over each electron
micrograph and counting the number of points falling on the
components of interest and the number of points falling on the
glomerulus. Volume density of mesangium (Vv mesangium/glom)
was the sum of Vv(mes cell/glom) and Vv(mes matrix/glom).
Volume density of renal cortical interstitium [Vv(int/cortex)]
was measured in ten randomly selected areas by the method of
point-counting on the light microscopic sections at a magnifica-
tion of x400 using a 100-point, calibrated, eyepiece grid as we
have previously described [39]. We only counted the points lying
on interstitial tissue (Pi). The volume density of cortical intersti-
tium was calculated from:
IPi
Vv(intJcortex) = (pm3/Jxm3)100>< 10
Statistics
Results were presented as mean SD or standard error (SE).
The significance of differences among three or four groups was
assessed using one-way analysis of variance (ANOVA) with
Duncan's multiple range comparison test or Kruskal-Wallis test.
Results between two groups were analyzed by Wilcoxon's rank
sum test. A P value of less than 0.05 was considered significant.
Results
Body weight and renal function
There were no differences in food intake among the experimen-
tal groups (Table 1). Body weight of the nontreated rats with
PA-HC or Sal-HC was significantly lower than that of the
PA-normal or Sal-normal (P < 0.05). Yet it was not significantly
different between the three groups of rats with PA-HC. Previous
study also showed that chronic cholesterol-fed rats with or without
PA nephrosis had lower body weights than normal rats fed
standard food [28, 30], possibly due to increased catabolism.
Plasma concentrations of urea nitrogen and creatinine were not
significantly different among the experimental groups (Table 1).
Plasma lipids
At 32 weeks, the concentrations of plasma total cholesterol and
LDL-C + VLDL-C in the rats with PA-HC or Sal-HC were
EC
ci,00
Fig. 1. Urinaiy protein excretion in the groups of
rats with PA-I-IC and untreated PA-normal (A),
and in the groups of rats with Sal-HC and Sal-
Normal (B) at selected time intervals. Symbols in
A are: () untreated PA-HC; () probucol-
treated PA-HC; (L) vitamin E-treated PA-HC;(ti) untreated PA-normal. ? < 0.05
comparing probucol- or vitamin E-treated PA-
HC or untreated PA-normal versus untreated
PA-HC (A). Symbols in B are: () untreated
SAL-HC; () probucol-treated Sal-HC; (LI)
vitamin E-treated Sal-HC; (Li) Sal-normal.
**P < 0.05 comparing untreated Sal-HC versus
Sal-normal (B).
prohucol treatment did not decrease the concentrations of total
cholesterol and LDL-C + VLDL-C in the rats with Sal-HC.
The fasting plasma level of triglycerides in the experimental
groups of rats was normal, and treatment with probucol or vitamin
E did not affect them.
Proteinuria
The untreated rats with PA-HC presented with relatively heavy
proteinuria excreting more than 200 mg per day thoughout the
study. Although the untreated rats with PA-normal also presented
*
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significantly higher than those of PA-normal or Sal-normal (P <
0.05) (Table 1). In fact, the value of plasma total cholesterol in the
rats with PA-normal was not different from Sal-normal from week
16 onwards. Treatment with probucol in rats with PA-HC showed
a tendency toward the reduced levels of total cholesterol, LDL-C
+ VLDL-C and HDL-C than the nontreated rats with PA-HC.
Nonetheless, the difference was not statistically significant (Table
1). In rats with PA-normal, administration of probucol reduced
the total cholesterol level with a borderline significance (P >
0.08), but not LDL-C + VLDL-C nor HDL-C. In addition,
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Table 2. Susceptibility of plasma VLDL + LDL to Cu catalyzed
oxidation in experimental animals
TBARS
Group nmol MDA/mg protein
PA-HC
Nontreated 1.92 0.45
Probucol-treated 0.98 0.04a
Vitamin E-treated 1.38 0.lla
PA-normal
Nontreated 1.30 0.53"
Probucol-treated 0.45 0.42
Vitamin F-treated 0.56 0.35
Sal-HC
Nontreated 1.05 0.49"
Probucol-treated 0.52 0.14
Vitamin E-treated 0.55 0.07
Sal-normal 0.95 003"
Data represent the mean so of three comparable experiments, each
carried Out 10 duplicate.
aP < 0.05 comparing probucol- or vitamin E-treated versus nontreated
in PA-HC group
b P < 0.05 comparing PA-normal nontreated, Sal-HC nontreated, or
Sal-normal versus PA-HC nontreated
Table 3. Renal cortical TBARS in experimental animals
TBARS
Group nrnol MDA/mg protein
PA-HC
Nontreated 4.40 0.75
Probucol-treated 2.97 0.58
Vitamin F-treated 3.18 0.63k'
PA-normal
Nontreated 3.07 0.64"
Probucol-treated 2.73 0.65
Vitamin E-treated 1.93 0.10
Sal-HC
Nontreated 3.01 0.04"
Probucol-treated 1.87 1.27
Vitamin E-treated 2.62 0.39
Sal-normal 1.64 0.11"
Data represent the mean 5D of three comparable experiments, each
carried out in duplicate.
a P < 0.05 comparing probucol- or vitamin E-treated versus nontreated
in PA-HC group
b P < 0.05 comparing PA-normal nontreated, Sal-HC nontreated, or
Sal-normal versus PA-HC nontreated
with proteinuria, the amounts were lower than the untreated
PA-HC group (Fig. 1A). Treatment with probucol or vitamin E in
the rats with PA-HC significantly reduced the amounts of pro-
teinuria from week 4 onwards (Fig. 1A). At the end of the study,
the nontreated rats with PA-HC excreted 207 105 mg protein
per day, whereas the probucol-treated rats and the vitamin
E-treated rats excreted 100 46 mg per day and 104 35 mg per
day, respectively. Confirming the previous reports [19, 22, dietary
antioxidants in the rats with PA-normal also reduced the amounts
of proteinuria (data not shown).
The untreated rats with Sal-HG showed mild proteinuria at 12,
16 and 20 weeks of experiment excreting around 90 mg per day.
The amounts of urinary protein excretion in this group were
significantly larger (P < 0.05) than those of Sal-normal. After 24
weeks, however, proteinuria disappeared. The addition of antioxi-
Fig. 2. Renal histopathology in rats with PA-HG. Representative glomeruli
from a nontreated rat show mesangial expansion and segmental sclerosis
(A). The severity of the lesions become markedly reduced in the glomeruli
from a vitamin E-treated rat (B). (PAS stain, X200).
dants, probucol or vitamin E, did not affect the excretion of
urinary protein (Fig. IB).
Susceptibility of VLDL and LDL to Gu '-catalyzed oxidation
Plasma VLDL and LDL fractions isolated from the untreated
rats with PA-HG produced greater TBARS after incubation with
Gu than the untreated rats with PA-normal or Sal-HG or
Sal-normal (Table 2). The administration of probucol or vitamin
E in the rats with PA-HC rendered plasma VLDL + LDL
significantly resistant to Cu k-mediated oxidation. The degree of
in vitro lipid peroxidation was not significantly different between
the two treated groups.
Renal cortical lipid peroxidation
The untreated rats with PA-HC showed significantly higher
renal cortical TBARS values than the untreated rats with PA-
normal or Sal-HG (Table 3). Renal lipid peroxides in PA-normal
or Sal-HG rats were increased compared with Sal-normal con-
trols. The administration of probucol or vitamin E in the rats with
PA-HG produced a significant fall (P < 0.05) in renal cortical
TBARS. There was no significant difference in the renal cortical
TBARS between the two treated groups.
Pathology
Between 219 and 410 glomeruli per animal were examined in all
the experimental groups of rats. FSGS lesions were observed in all
the nontreated rats with PA-HG involving 3 to 33% (mean 13.1 ±
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Table 4. Morphologic data in experimental animals
Group N
Glomerular
area
pm2
Glomeruli
with FSGS
%
Volume density (Vv)
Number of
EDI-positive cells
per glomerular
cross section
Mesangium!
glomerulus
Interstitium!
cortex
pin3/pn3
PA-HC
Nontreated 14 9315 668 13.1 10.8 0.15 0.02 (6) 0.06 0.03 2.54 1.41
Probucol-treated 15 9186 616 6.1 37 0.11 o.Ola (6) 0.04 0.03a 1.32 0.54
Vitamin F-treated 15 8970 645 4.8 4.7k' 0.10 0.02a (6) 0.02 0.02a 1.12 0.61
PA-normal
Nontreated 5 7742 202i 5.9 4.6c 0.12 002b (3) 0.04 0.03c 1.04 1.03i
Probucol-treated 5 6892 101 1.0 0.4 ND 0.01 0.01 0.25 0.12
Vitamin E-treated 4 6685 302 1.8 1.8 ND 0.01 0.01 0.21 0.21
Sal-HC
Nontreated 6 7375 410b 0 0.11 002b (4) 0.002 0.005 0.55 0.26i
Probucol-treated 6 7649 432 0.1 0.2 0.10 0.01 (3) 0.001 0.001 0.47 0.32
Vitamin E-treated
Sal-normal
4
6
7606 310
6052 265b
0.1 0.2
0
0.10 0.01 (3)
0.09 001b (4)
0.002 0.005
0.001 0.001
0.75 0.70
0.32 0.14i
Values are mean SE. Values in parentheses refer to the number of animals in which Vv(mesangium/glomerulus) was measured. ND is not done.
For other abbreviations see Table 1.
aP < 0.05 comparing probucol- or vitamin E-treated versus nontreated in PA-HC group
b P < 0.05 comparing PA-normal nontreated, Sal-HC nontreated, or Sal-normal versus PA-HC nontreated
P < 0.05 comparing PA-normal nontreated versus PA-HC nontreated
10.8%) of the glomeruli (Fig. 2A). Lesions of FSGS frequently
had foam cells and/or hyalinosis. In the nontreated rats with
PA-normal, lesions of FSGS were also observed affecting I to
16% (mean 5.9 4.6%) of the glomeruli. The difference in
frequency of FSGS between these two groups was significant (P <
0.05). Probucol or vitamin E treatment in the rats with PA-HC
caused a significant reduction (P < 0.05) in the magnitude of
FSGS (Fig. 2B). Confirming the previous reports [19, 22], we
obsereved that treatment with probucol or vitamin E reduced the
frequency of FSGS in rats with PA-normal. In the three experi-
mental groups of rats with Sal-HC, however, the occurrence of
FSGS lesion was almost negligible (Table 4).
The mean glomerular area was significantly increased (P <
0.05) in the nontreated rats with PA-HC (9315 668 xm2)
compared with the untreated rats with PA-normal (7742 202
tim2) or Sal-FTC (7375 410 tim2). Treatment with probucol or
vitamin E in rats with PA-HC showed a tendency toward the
reduced mean glomerular area, but the difference was not signif-
icant (Table 4).
Mesangial volume density [Vv(mesangium/glom)] in the non-
treated rats with PA-HC was significantly increased (P < 0.05)
compared with untreated rats with PA-normal or Sal-HC. In-
crease in both cells and matrix contributed to the mesangial
expansion in the former. The administration of probucol or
vitamin E in the rats with PA-HC produced a significant reduction
of Vv(mesangium/glom) (Table 4).
Tubules in the nontreated rats with PA-HC showed focal
atrophy or loss to a variable degree with infiltration of mononu-
clear cells and collagen laydown in interstitium. Some atrophic
tubules were dilated containing protein casts. Vv(int/cortex) in
rats with PA-FTC alone was significantly greater than rats with
PA-normal alone. Probucol or vitamin E administration in the
rats with PA-HC caused a significant reduction of Vv(int/cortex).
Immunohistochemical observations
Immunohistochemical staining using mAbs, OL1O and 0L13,
demonstrated focal segmental distribution of Ox.LDL in the
glomeruli of rats with PA-HC, mainly in the lesions of FSGS (Fig.
3A). In the nonsclerotic glomeruli, Ox-LDL was also shown to be
present occasionally either intracellularly or extracellularly (Fig.
3B). The intensity or extent of staining for Ox-LDL in the
glomeruli was decreased in the probucol- or vitamin E-treated
rats in association with decrease in FSGS lesion size (Fig. 3C). In
the glomeruli of rats with PA-normal, focal segmental specks for
Ox-LDL were also present along the peripheral capillary walls or
in the lesions of FSGS but to a smaller degree than PA-HC.
The number of glomerular macrophages in the nontreated rats
with PA-HC was significantly larger than that in the nontreated
rats with PA-normal or Sal-HC. The administration of probucol
or vitamin F in PA-HC rats produced a significant fall in the
number of macrophages (Figs. 4). ED1-positive cells were also
present in the interstitium of the three experimental groups of rats
with PA-HC, and were more prevalent in the nontreated group
than the treated groups.
Discussion
This study demonstrates that alimentary hypercholesterolemia
aggravates the renal damage in association with increased renal
lipid peroxides and lipoprotein susceptibility to in vitro oxidation
in rats with chronic PA nephrosis and that administration of
probucol or vitamin F can slow the progression of renal injury in
rats with PA-FTC.
Hypercholesterolemia is observed in rats with chronic PA
nephrosis [22], yet, it seems to be transiently present after PA
injection as shown by Diamond and Karnovsky [26] and ourselves.
In the present study, chronic PA nephrotic rats with dietary
hypercholesterolemia showed significantly greater susceptibility of
plasma VLDL + LDL to in vitro oxidation and increased renal
cortical MDA than those without, suggesting that hypercholester-
olemia could make lipoproteins more susceptible to oxidation. We
also found increased renal cortical lipid peroxides in the rats with
Sal-HC compared to normal controls. Histologic renal injury,
however, was not present in Sal-HC, thus confirming the view that
lipids are not an initiator but a modulator of renal disease [1—3].
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Fig. 3. Immunohistochemical identification of oxidized LDL (Ox-LDL) in
representative glomeruli of rats with PA-HC. Sections were labeled with
mAb OL-lO and counterstained with hematoxylin. Heavy deposition of
Ox-LDL is shown in the sclerotic segments of a glonierulus from a
nontreated rat (A). In nonscierotic glomerulus from a nontreated rat,
there is intracellular (arrowheads) or extracellular localization of Ox-LDL
(B). The intensity of Ox-LDL staining is diminished in the glomerulus
from a probucol-treated rat (C). (Immunoperoxidase, X400). Reproduc-
tion of this figure was made possible by a grant from Green Cross
Corporation, Seoul, Korea.
Fig. 4. Immunohistochemical staining for rat monocyte/macrophages in representative glomeruli of rats with PA-HC. Sections were labeled with ED 1. There
are several ED1 + cells including a foam cell (arrowhead) in the glomerulus from a nontreated rat (A). In contrast, few EDI + cells are shown in the
glomerulus from a vitamin E-treated rat (B). (Immunoperoxidase, x400). Reproduction of this figure was made possible by a grant from Green Cross
Corporation, Seoul, Korea.
Administration of probucol or vitamin E in the rats with
PA-HC significantly reduced the susceptibility of plasma VLDL +
LDL to in vitro oxidation and renal cortical MDA. Thus, the
resistance to in vitro lipid peroxidation caused by treatment with
probucol or vitamin E seems to be translated into resistance to in
vivo lipid peroxidation that occurs in the renal cortex.
As is the case for human glomerular diseases showing deposi-
tion of apolipoprotein B-containing lipoproteins in the glomeruli
[40], intraglomerular lipid deposition has been demonstrated by
oil red 0 staining in the rats with PA-HC [221. Increased collagen
[41] or other extracellular matrix [42] in the diseased glomeruli
together with higher circulating lipoprotein levels may contribute
to the retention of LDL in the mesangial matrix. When the LDL
is trapped in the mesangial matrix with depleted antioxidants, it
may be oxidized by free radical process. The source of oxygen free
radicals in the glomeruli of rats with PA-HC is not evident.
Hypoxanthine, an intermediate metabolite of PA [43], can serve
as a substrate for oxygen free radical generation via the xanthine
oxidase system [14]. Free radicals produced at the time of PA
delivery may cause not only the podocyte injury [14], but also the
oxidation of LDL in the rats with PA-HC. In addition, several in
vitro studies suggest that the radicals may be derived from
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mesangial cells or infiltrating macrophages [44—48]. We demon-
strate the occurrence of Ox-LDL in the glomeruli of rats with
PA-HC by immunostaining indicating that oxidative modification
of LDL occurs in vivo. Furthermore, probucol or vitamin E
administration diminished the extent or intensity of staining for
Ox-LDL. Since Ox-LDL is mainly present in the lesions of FSGS,
the decrease in staining intensity may reflect not only a reduction
of oxidation of LDL but also a decrease in FSGS lesion size in the
treated groups.
In the present investigation, we demonstrate that infiltrating
glomerular macrophages are significantly more prevalent in the
rats with PA-HC than the rats with PA-normal or Sal-HC using
the staining with ED1. Although plasma cholesterol level in rats
with Sal-HC was much greater than PA-normal rats, no significant
difference in the number of glomerular macrophages was seen
between the two groups. Thus, infiltration of glomerular macro-
phages may not be directly related to hypercholesterolemia.
Therapy with probucol or vitamin E significantly reduced the
number of glomerular macrophages in the rats with PA-HC. In
contrast to vitamin E, which is without hypocholesterolemic effect
[91, probucol is known to have a cholesterol-lowering effect [50,
511. Nonetheless, probucol did not significantly reduce the plasma
cholesterol levels in our rats with PA-HC. Thus, the reduction of
glomerular macrophages could be attributed to antioxidant activ-
ity of probucol rather than its hypocholesterolemic effect. The
occurrence of Ox-LDL in the glomeruli of rats with PA-HC may
recruit circulating monocytes [4] leading to the accumulation of
macrophages in the glomeruli, whereas antioxidants inhibit the
process. Activated macrophages secrete cytokines, growth factors,
vasoactive substances, coagulation factors, reactive oxygen species
and proteolytic enzymes [521. The infiltrating glomerular macro-
phages may be an effector mechanism for the progression of initial
glomerular injury to glomeruloscierosis by augmenting mesangial
cell proliferation in nonimmune glomerular disorders [53, 54].
Furthermore, macrophages have a large number of scavenger
receptors and accumulate Ox-LDL within cells, resulting in foam
cell formation. When the foam cells die, the release of cytotoxic
components could cause a loss of glomerular cells and contribute
to the eventual glomeruloscierosis as originally proposed in
atherogenesis [8, 55]. These considerations lead us to believe that
administration of antioxidant, probucol or vitamin E, can prevent
the development of FSGS in rats with PA-HC possibly via
reductions in the number of glomerular macrophages or foam
cells.
In summary, the present studies demonstrate that alimentary
hypercholesterolemia aggravates proteinuria and histologic injury
in association with increased renal lipid peroxides and lipoprotein
susceptibility to in vitro oxidation in rats with chronic PA nephro-
sis, whereas antioxidant ameliorates these processes. This obser-
vation suggests that a dietary antioxidant, such as probucol or
vitamin E, attenuates chronic progressive renal injury in rats with
PA-HC possibly by making lipoproteins resistant to oxidation and
by limiting infiltration of macrophages in the glomeruli.
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